1672 — Ascletis Pharma Income Statement
0.000.00%
Last trade - 00:00- HK$6.05bn
- HK$3.98bn
- CNY1.28m
Annual income statement for Ascletis Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 35 | 76.9 | 54.1 | 56.6 | 1.28 |
| Cost of Revenue | |||||
| Gross Profit | -23.5 | 39.2 | -24.7 | 26 | 0.735 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 230 | 258 | 346 | 181 | 297 |
| Operating Profit | -195 | -181 | -292 | -124 | -295 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -209 | -199 | -315 | -145 | -301 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -209 | -199 | -315 | -145 | -301 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -209 | -199 | -315 | -145 | -301 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -209 | -199 | -315 | -145 | -301 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.196 | -0.181 | -0.239 | -0.136 | -0.311 |